Nasonex (Mometasone Furoate)

Mometasone furoate, the active ingredient in Nasonex, is a corticosteroid presented as a nasal spray for intranasal use. It is indicated for the treatment of allergic rhinitis and nasal polyps in adults and children, helping to reduce nasal inflammation and congestion.

GNH USA supplies Nasonex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nasonex is a topical corticosteroid used to manage inflammatory conditions of the nasal passages.

Allergic rhinitis: reduces nasal congestion, sneezing and itching caused by seasonal or perennial allergens. Nasal polyps: decreases polyp size and improves nasal airflow, relieving obstruction and associated symptoms.

Nasonex may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Epistaxis (nosebleed) - Throat irritation or dryness - Cough - Altered taste or bitter taste

Serious or Rare Side Effects: - Nasal septal perforation - Severe allergic reaction (anaphylaxis) - Vision changes or cataract formation - Adrenal suppression with prolonged high‑dose use - Opportunistic fungal infection of the nasal cavity

Before using Nasonex, consider the following safety measures.

Pregnancy: Category C; discuss potential risks with a healthcare professional. Breastfeeding: Use only if the benefit outweighs potential infant exposure. Recent nasal surgery or trauma: Avoid use until healing is complete. Systemic corticosteroid therapy: Monitor for additive systemic effects. Immunocompromised patients: Watch for increased risk of infection. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nasonex can interact with other medicines; review the following categories.

Major Interactions (Avoid): - Systemic corticosteroids: may increase systemic glucocorticoid exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise mometasone levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole). - Antifungal azoles and certain antibiotics that affect steroid metabolism. - Live vaccines: potential reduced vaccine efficacy. - Herbal supplements such as St. John’s wort that induce CYP3A4. - Other intranasal medications: assess for additive local irritation.